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httpsWHAT THIS PAPER ADDS
This paper presents the ﬁrst international consensus on creation of a minimum and optimum core data set for
registries devoted to peripheral arterial revascularisation. A modiﬁed Delphi approach with online interaction
was used to achieve consensus among international experts from multiple countries. The concept of simple to
more complex levels of data capture allows harmonisation at all levels, despite variation among registries.
Adoption of a standard variable set by the national registries within the International Consortium of Vascular
Registries will provide opportunities for more advanced collaborations, including amalgamation of large scale
international data for assessment of outcomes after the introduction of new techniques and devices.Objective/Background: To achieve consensus on the minimum core data set for evaluation of peripheral arterial
revascularisation outcomes and enable collaboration among international registries.
Methods: A modiﬁed Delphi approach was used to achieve consensus among international vascular surgeons and
registry members of the International Consortium of Vascular Registries (ICVR). Variables, including deﬁnitions,
from registries covering open and endovascular surgery, representing 14 countries in ICVR, were collected and
analysed to deﬁne a minimum core data set and to develop an optimum data set for registries. Up to three
different levels of variable speciﬁcation were suggested to allow inclusion of registries with simpler versus more
complex data capture, while still allowing for data aggregation based on harmonised core deﬁnitions.
Results: Among 31 invited experts, 25 completed ﬁve Delphi rounds via internet exchange and face to face
discussions. In total, 187 different items from the various registry data forms were identiﬁed for potential
inclusion in the recommended data set. Ultimately, 79 items were recommended for inclusion in minimum core
data sets, including 65 items in the level 1 data set, and an additional 14 items in the more speciﬁc level 2 and 3
recommended data sets. Data elements were broadly divided into (i) patient characteristics; (ii) comorbidities;
(iii) current medications; (iv) lesion treated; (v) procedure; (vi) bypass; (vii) endarterectomy (viii) catheter based
intervention; (ix) complications; and (x) follow up..D. and J.C. share last authorship.
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218 Christian-Alexander Behrendt et al.Conclusion: A modiﬁed Delphi study allowed 25 international vascular registry experts to achieve a consensus
recommendation for a minimum core data set and an optimum data set for peripheral arterial revascularisation
registries. Continued global harmonisation of registry infrastructure and deﬁnition of items will overcome
limitations related to single country investigations and enhance the development of real world evidence.
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RegistriesINTRODUCTION
Although peripheral arterial disease (PAD) remains an
increasing burden for national healthcare systems with
>200 million people affected worldwide,1 many questions
regarding treatment of this disease cannot be answered
using evidence from trials. Thus, in the absence of such
evidence, many recommendations in international practice
guidelines are built on expert consensus.2e4 As there are
only a few randomised controlled trials (RCTs) with well
known problems of selection bias and limited external val-
idity, with reasonable efforts registries and registry based
cohort studies can help to ﬁll the gaps. Registries allow
evaluation of treatment practice patterns, medical device
evaluation, and can assess convergence of real world and
RCT evidence.5 Although multiple national vascular regis-
tries exist, lack of consensus around variables (and their
deﬁnitions) makes aggregation and comparison of ﬁndings
difﬁcult.
International collaborations such as the International
Consortium of Vascular Registries (ICVR; www.icvr-initiative.
org) can help harmonise cross border research. The ICVR is
comprised of countries with vascular surgery registries,
including the Vascular Quality Initiative (VQI; www.vqi.org)
in the USA and the Vascunet Collaboration, consisting of
vascular registries from 12 countries in Europe and Aus-
tralasia (www.vascunet.org). The ICVR was launched in 2014
with the goal of establishing a collaborative platform across
registries to share data in order to improve the quality of
vascular health care.6 Contributions regarding abdominal
aortic aneurysms (AAA) and carotid artery stenosis were
recently published by this collaboration.6e9 For this project,
ICVR members aimed to apply a modiﬁed Delphi approach
to achieve agreement on a minimum core data set and to
create an optimum data set for registries capturing surgical
and interventional PAD treatments.
METHODS
The Delphi approach is widely accepted and used to gain
consensus among a panel of experts,10 and has previously
been used in various specialties, including vascular sur-
gery.11e15 Representatives of 14 national vascular registries
participating in the ICVR from Australia (Australasian
Vascular Audit), Denmark (Karbase), Finland (HUSvasc),
Germany (GermanVasc and Aortic Registry of the German
Vascular Society), Hungary (Hungarian Vascular Registry),
Iceland (Isvasc), Italy (Italian Vascular and Endovascular
Registry), New Zealand (Australasian Vascular Audit), Nor-
way (NORKAR), Spain, Sweden (Swedvasc), Switzerland(Swissvasc), and the USA (VQI) submitted their registries’
current data sheets and deﬁnitions of data elements. An
extensive narrative review of the literature was conducted
to identify additional items in registry based studies on
PAD. All participants in this study agreed to the scope of
items identiﬁed through the abovementioned process.
Members of the ICVR were then invited to participate in
web based anonymised electronic questionnaires. Open
source software (www.limesurvey.org) was used to
generate the questionnaires. The participants could only
submit one set of answers in each Delphi round. Following
each round, a structured report, including anonymised
group responses, mean results with SDs, as well as com-
ments, were forwarded to the participants by email before
they were invited to the next round. Each participant was
asked to indicate whether they agreed that individual var-
iables should be included in the consensus data set, and
each item was scored on a ﬁve point Likert scale comprising
“strongly agree”, “agree”, “neutral”, “disagree”, and “strongly
disagree”. Additionally, a free text comment could be sub-
mitted for each item. Items repeatedly rated with “strongly
agree” or “agree” were recommended for the minimum
data set. Items repeatedly rated with “strongly disagree” or
“disagree” were eliminated from consideration. If consensus
was not achieved after three rounds, the remaining items
were discussed by the experts in two face to face ICVR
meetings and added to the minimum data set if 80% of the
experts supported the variable.
During this evaluation, it became apparent that it was
important to determine not only which variables to include,
but also what level of detail was needed for each variable
included. By analysing each current national registry, it was
determined that considerable variation existed in the level
of detail collected, and in some cases the deﬁnition of the
variables. In order to allow different levels of detail to be
collected by different registries, but still allow harmo-
nisation, three “levels” of variable recording detail but with
common core deﬁnitions were created. Thus, reporting
levels were stratiﬁed for data elements as level 1, 2, and 3,
ranging from minimum to optimum. Reporting level 1 for
variables were considered the minimum information
necessary and typically have a simple input (yes, no) or
simple numeric range. Level 2 and 3 variables have addi-
tional increasing speciﬁcity and granularity. For example,
reporting the comorbidity of diabetes includes yes/no in
reporting level 1. The more speciﬁc reporting level 2 in-
cludes the type of medical treatment (insulin, oral antidia-
betic, etc.), whereas reporting level 3 includes HbA1c level
Table 1. Seventy-nine items in the minimal core and optimal data set for registries evaluating peripheral arterial revascularisation.
Category Variable Reporting Level 1 Reporting Level 2 Reporting Level 3 Comments Reference
1) Patient
Characteristics
Birth Date Day (dd), month (mm), and
year (yyyy) of birth
Used to calculate age at time
of procedure for subsequent
analysis and de-identiﬁed
data sharing. If regulations do
not allow date collection, age
(years) can be substituted.
Sex Female, Male Female, Male, Trans
female, Trans male
Sex at birth. Trans female has
transitioned from female sex
to male gender; Trans male
has transitioned from male
sex to female gender.
Weight Body Weight in kg
Height Body Height in cm
Functional Status Full activity, Light Work,
Self Care, Assisted Care,
Bedbound
Add disease speciﬁc
quality of life survey,
such as Vascu-Qol-6
A person’s level of
functioning in terms of their
ability to care for them self,
daily activity, and physical
ability (walking, working
etc.).
Oken MM, Creech RH, Tormey
DC, Horton J, Davis TE,
McFadden ET, et al. Toxicity and
response criteria of the Eastern
Cooperative Oncology Group.
Am J Clin Oncol. 1982;5(6):649
e55.
Nordanstig J, Wann-Hansson C,
Karlsson J, Lundström M,
Petterson M, Morgan MBF.
Vascular Quality of Life
Questionnaire-6 faciliates health
related quality of life assessment
in peripheral arterial disease. J
VascSurg 2014;59:700-7.
Ambulation Fully Ambulatory,
Ambulate with Prosthesis,
Ambulate with Assistive
Device, Wheelchair,
Bedbound
Add walking distance
survey such as Walking
Improvement
Questionnaire or GPS
monitored walking
ASA Grade Normal healthy patient (1),
mild systemic disease (2),
severe systemic disease (3),
severe systemic disease that
is a constant threat to life (4),
moribund patient who is not
expected to survive without
the operation (5), declared
brain dead patient
Owens WD, Felts JA, Spitznagel
EL. ASA Physical Status
Classiﬁcations: A Study of
Consistency of
Ratings.Anesthesiology
1978;49:239-243. Recent
update: https://www.asahq.org/
resources/clinical-information/
asa-physical-status-classiﬁcation-
system
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Table 1-continued
Category Variable Reporting Level 1 Reporting Level 2 Reporting Level 3 Comments Reference
2) Patient Co-
morbidities
Diabetes No, Yes If Yes: Treated with:
Insulin, Oral Antidiabetic,
Both, Diet alone, No
Treatment
HbA1c in % Yes ¼ clinical diagnosis
documented in medical
record based on
Fasting  7 mmol/L or post
glucose  11.1 mmol/L and/
or HbA1c  6.5% and/or
antidiabetic medication.
Stoner MC, Calligaro KD, Chaer
RA, Dietzek AM, Farber A,
Guzman RJ, et al. Reporting
standards of the Society for
Vascular Surgery for
endovascular treatment of
chronic lower extremity
peripheral artery disease. J Vasc
Surg. 2016;64(1):e1-e21.
Kumar R, Nandhini LP,
Kamalanathan S, Sahoo J,
Vivekanadan M. Evidence for
current diagnostic criteria of
diabetes mellitus. World J
Diabetes. 2016;7(17):396e405.
Current Renal
Function
Normal, Abnormal Serum Creatinine (in
mmol/l or mg/dl)
Glomerular ﬁltration
rate (GFR) in ml/min
(Cockcroft-Gault
calculation)
As deﬁned by the National
Kidney Foundation::eGFR
<60 mL/min/1.73 m2 on two
occasions separated by 3
months and that is not
associated with a transient,
reversible condition such as
volume depletion.
National Kidney F. K/DOQI
clinical practice guidelines for
chronic kidney disease:
evaluation, classiﬁcation, and
stratiﬁcation. American journal
of kidney diseases: the ofﬁcial
journal of the National Kidney
Foundation. 2002;39(2 Suppl
1):S1-266.
Current Dialysis No, Yes Duration of dialysis
dependence (years)
Tobacco Use Current Smoker, Former
Smoker, Never Smoked
If Former Smoker: Quit
Date
If Current or Former
Smoker: Pack Years
(py) Smoked
Stoner MC, Calligaro KD, Chaer
RA, Dietzek AM, Farber A,
Guzman RJ, et al. Reporting
standards of the Society for
Vascular Surgery for
endovascular treatment of
chronic lower extremity
peripheral artery disease. J Vasc
Surg. 2016;64(1):e1-e21.
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Current Ischaemic
Heart Disease
No, Yes If Yes: Asymptomatic,
Angina only during
Strenuous or Prolonged
Physical Activity,
Symptoms with Everyday
Living Activities, Inability
to Perform any Activity
Without Angina or Angina
at Rest
Yes ¼ current angina or
positive stress test indicating
ischaemic heart disease
Lee TH, Marcantonio ER,
Mangione CM, Thomas EJ,
Polanczyk CA, Cook EF, et al.
Derivation and prospective
validation of a simple index for
prediction of cardiac risk of
major noncardiac surgery.
Circulation. 1999;100(10):
1043e9.
Prior Myocardial
Infarction
No, Yes Add Prior
Revascularisation: CABG,
PCI
Add timing of MI and
CABG/PCI:
MI  6 Months, >
6 Months; CABG/
PCI < 5 years, CABG/
PCI > 5 years
Yes ¼ clinical history
documented in medical
record
Lee TH, Marcantonio ER,
Mangione CM, Thomas EJ,
Polanczyk CA, Cook EF, et al.
Derivation and prospective
validation of a simple index for
prediction of cardiac risk of
major noncardiac surgery.
Circulation. 1999;100(10):
1043e9.
Congestive Heart
Failure
Never, Former, Current If Current: New York Heart
Association (NYHA)-
Classiﬁcation for heart
failure (Class I to IV)
Current Ejection
Fraction in %
Current/former ¼ clinical
diagnosis/history
documented in medical
record, based onPonikowski
et al. (2016) andLee et al.
(1999): Patient has a history
of or current symptoms of
congestive heart failure,
pulmonary oedema, or
paroxysmal nocturnal
dyspnea, physical
examination showing
bilateral rales or S3 gallop, or
chest radiograph showing
pulmonary vascular
redistribution.
Lee TH, Marcantonio ER,
Mangione CM, Thomas EJ,
Polanczyk CA, Cook EF, et al.
Derivation and prospective
validation of a simple index for
prediction of cardiac risk of
major noncardiac surgery.
Circulation. 1999;100(10):
1043e9.
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ble 1-continued
ategory Variable Reporting Level 1 Reporting Level 2 Reporting Level 3 Comments Reference
Ponikowski P, Voors AA, Anker
SD, Bueno H, Cleland JG,
CoatsAJ, et al. 2016 ESC
Guidelines for the diagnosis and
treatment of acute and chronic
heart failure: The Task Force for
the diagnosis and treatment of
acute and chronic heart failure
of the European Society of
Cardiology (ESC). Developed with
the special contribution of the
Heart Failure Association (HFA)
of the ESC. European journal
of heart failure. 2016;18(8):
891e975.
Cardiac
Arrhythmia
Never, Former, Current If Current: Atrial,
Ventricular, Previous
Ablation, AV-Block with
Pacemaker, Deﬁbrillator
(ICD), Previous Ablation
and Pacemaker or ICD,
Other
Yes ¼ clinical diagnosis
documented in medical
record, including atrial
ﬁbrillation, bradycardia,
conduction disorders,
premature contraction,
tachycardia, ventricular
ﬁbrillation, other rhythm
disorders.
Chronic
Obstructive
Pulmonary
Disease
Never, Former, Current If Current: No Treatment,
Medical Treatment, Home
Oxygen
Yes ¼ clinical diagnosis
documented in medical
record of chronic obstructive
pulmonary disease or
pulmonary medical
treatment. As deﬁned
byStoner et al. (2016).
Stoner MC, Calligaro KD, Chaer
RA, Dietzek AM, Farber A,
Guzman RJ, et al. Reporting
standards of the Society for
Vascular Surgery for
endovascular treatment of
chronic lower extremity
peripheral artery disease. J Vasc
Surg. 2016;64(1):e1-e21.
Hypertension Never, Former, Current If Current: Treated
controlled, treated
uncontrolled (blood
pressure > 140/90
despite treatment)
Blood pressure > 140/90 or
medical treatment.
Mancia G, Fagard R, Narkiewicz
K, Redon J, Zanchetti A, Böhm M,
et al. 2013 ESH/ESC Guidelines
for the management of arterial
hypertension. Eur Heart J.
2013;34:2159-2219.
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Prior PAD
Revascularisation
No, Yes If Yes: Interventional,
Surgical, Both
Location: Inﬂow,
Outﬂow; Type:
Intervention, Bypass,
Endarterectomy; Leg:
R/L/Aorta
Prior Amputation Minor, Major If Yes: Level: Toe(s),
transmetatarsal, below
knee, through knee,
above knee, higher of R/L
leg
Conte MS, Geraghty PJ, Bradbury
AW, Hevelone ND, Lipsitz SR,
Moneta GL, et al. Suggested
objective performance goals and
clinical trial design for evaluating
catheter-based treatment of
critical limb ischemia. J Vasc
Surg. 2009;50(6):1462e73 e1-3.
3) Current
Medication
Aspirin No, Yes If Yes:  100 mg/d, 101
e320 mg/d, >320 mg/d
Add medication
prescribed at
discharge.
Medication in effect at time
of procedure.
Other Platelet
Inhibitor
No, Yes if Yes, medication name Add medication
prescribed at
discharge.
Medication in effect at time
of procedure.
Statin No, Yes If Yes: Low Dose, High
Dose
Add medication
prescribed at
discharge.
Medication in effect at time
of procedure.
Anticoagulant No, Yes If Yes: Vitamin K
Antagonist, Thrombin
Inhibitor, Factor Xa
Inhibitor, Other
Add medication
prescribed at
discharge.
Medication taken chronically
before procedure (even if
stopped in preparation for
procedure).
4) Lesion
treated
Symptoms for
Right/Left Leg
Modiﬁed Rutherford-
Classiﬁcation: Asymptomatic,
Mild Claudication, Moderate
Claudication (>200m),
Severe Claudication
(<200m), Ischaemic Rest
Pain, Ulcer/Necrosis, Non-
healing Amputation, Both
Ulcer/Non-healing
Amputation, Acute Ischaemia
will include ref RAPID for the
modiﬁed Rutherford when
published
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Table 1-continued
Category Variable Reporting Level 1 Reporting Level 2 Reporting Level 3 Comments Reference
Foot Infection for
Right/Left Leg
No, Yes Grade 0 None, Grade 1
Mild, Grade 2 Moderate,
Grade 3 Severe
Mills, Joseph L. Sr., MD, et al.
(2014). The Society for Vascular
Surgery Lower Extremity
Threatened Limb Classiﬁcation
System: Risk Stratiﬁcation Based
on Wound, Ischaemia, and Foot
Infection (WIfI). Journal of
Vascular Surgery, Volume 59
(Issue 1) pp.220-pp.234.e2,
https://doi.org/10.1016/j.jvs.
2013.08.003
Tissue Loss
Severity for Right/
Left Leg
None, Grade 1, Shallow,
Grade 2, Deep, Grade 3,
Extensive
Mills, Joseph L. Sr., MD, et al.
(2014). The Society for Vascular
Surgery Lower Extremity
Threatened Limb Classiﬁcation
System: Risk Stratiﬁcation Based
on Wound, Ischaemia, and Foot
Infection (WIfI). Journal of
Vascular Surgery, Volume 59
(Issue 1) pp.220-pp.234.e2,
https://doi.org/10.1016/j.jvs.
2013.08.003
Ankle brachial
index for Right/
Left Leg
Highest ABI 1.3, ABI < 1.3
and  0.9, ABI < 0.9
and  0.7, ABI < 0.4, treated
leg
ABI exact measurement
R/L leg
ABI and TBI exact
measurement R/L leg
Aboyans V, Criqui MH, Abraham
P, Allison MA, Creager MA,
Diehm C, et al. Measurement
and interpretation of the ankle-
brachial index: a scientiﬁc
statement from the American
Heart Association. Circulation.
2012;126(24):2890e909.
Artery vs. Graft Native Artery, Bypass Graft Graft Conduit: Vein,
Prosthetic; Location:
Supra-Inguinal, Infra-
Inguinal
Add Graft Origin and
Insertion
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Artery Treated or
Bypassed
Aorta, iliac, femoral,
popliteal, tibial
Aorta, common Iliac,
external iliac,
common + external iliac,
internal iliac, common
femoral, superﬁcial
femoral, profunda
femoral, popliteal,
SFA + popliteal, anterior
tibial, posterior tibial,
peroneal, tibioperoneal
trunk, dorsal pedal,
plantar
Add Artery Segment:
Prox, Mid, Distal, as in
Popliteal P1, P2, P3
segments
Side for each
Lesion Treated
Right, Left, Aorta
Lesion Length Short (<5cm for aorto-iliac
and <25cm for
femoropopliteal lesions),
Long (5cm for aorto-iliac
and  25cm for
femoropopliteal lesions)
Length (cm) Acin F, de Haro J, Bleda S, Varela
C, Esparza L. Primary nitinol
stenting in femoropopliteal
occlusive disease: a meta-
analysis of randomized
controlled trials. Journal of
endovascular therapy: an ofﬁcial
journal of the International
Society of Endovascular
Specialists. 2012;19(5):585e95.
Aboyans V, Ricco J, Bartelink
MEL, Björck M, Brodmann M,
Cohnert T et al., 2017 ESC
Guidelines on the Diagnosis and
Treatment of Peripheral Arterial
Diseases, in collaboration with
the European Society for
Vascular Surgery (ESVS),
European Journal of Vascular
and EndovascularSurgery (2017),
http://dx.doi.org/10.1016/j.ejvs.
2017.07.018
Most Severe
Stenosis
Stenosis, Occlusion Bollinger Score:
Complete occlusion,
Stenosis >50% of
lumen, Stenosis of 25
e50% of lumen, 25%
stenosis of lumen
Bollinger A, Breddin K, Hess H,
Heystraten FM, Kollath J,
Konttila A, et al.
Semiquantitative assessment of
lower limb atherosclerosis from
routine angiographic images.
Atherosclerosis. 1981;38
(3e4):339e46.
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Table 1-continued
Category Variable Reporting Level 1 Reporting Level 2 Reporting Level 3 Comments Reference
Outﬂow from
Treated Artery
No outﬂow, one vessel,
two vessels, three vessels
Modiﬁed Society for
Vascular Surgery (SVS)
runoff score: from 0 to
19 points
Davies MG, Saad WE, Peden EK,
Mohiuddin IT, Naoum JJ,
Lumsden AB. Impact of runoff on
superﬁcial femoral artery
endoluminal interventions for
rest pain and tissue loss. J Vasc
Surg. 2008;48(3):619e25;
discussion 25e6.
5) Procedure Procedure Date Day (dd), month (mm), and
year (yyyy) of the procedure
Used to calculate length of
hospital stay for subsequent
analysis and de-identiﬁed
data sharing. If regulations do
not allow date collection,
length of stay (days) can be
substituted.
Living Location Home, Nursing Care
Facility, Homeless
Admission Date Day (dd), month (mm), and
year (yyyy) of admission if
hospitalised
Used to calculate length of
hospital stay for subsequent
analysis and de-identiﬁed
data sharing. If regulations do
not allow date collection,
length of stay (days) can be
substituted.
Discharge Date Day (dd), month (mm), and
year (yyyy) of discharge if
hospitalised
Used to calculate length of
hospital stay for subsequent
analysis and de-identiﬁed
data sharing. If regulations do
not allow date collection,
length of stay (days) can be
substituted.
Discharge
Destination
Home, Nursing Care
Facility, Rehabilitation
Facility, Homeless, Other
Performance Site Hospital Outpatient,
Hospital Inpatient,
Ambulatory Centre, Ofﬁce
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Urgency of the
Procedure
Elective, Urgent, Emergent Elective ¼ planned/
scheduled procedure;
urgent ¼ surgery within
24 hrs of admission or
patient can’t be discharged;
emergency ¼ surgery within
6 hrs of admission
Provider Specialty Angiologist/Vascular
Medicine, Cardiologist,
Radiologist, Surgeon,
Other
Multidisciplinary Team
Decision (MTD)
achieved prior to the
Procedure?
Type of Procedure Surgical Bypass,
Endarterectomy, Catheter
based Intervention, Hybrid
6) Bypass Surgical Bypass
Location for
Right/Left Leg
Ax-fem, Ax-bifem, Aorto-fem,
Aorto-bifem, Fem-fem, fem-
ATK popliteal, Fem-BTK
popliteal, Fem-tibial, Pop-
tibial, Fem/Pop-DP/plantar
Proximal and Distal
anastomosis location:
Supra-aortic, Thoracic
Aorta, Abdominal Aorta,
Common Iliac Artery,
External Iliac Artery,
Internal Iliac Artery,
Common Femoral Artery,
Deep Femoral Artery,
Superﬁcial Femoral Artery,
Popliteal Artery Above
Knee, Popliteal Artery
BelowKnee, Tibioperoneal
Trunk, Anterior Tibial
Artery, Posterior Tibial
Artery, Peroneal Artery,
Pedal Artery, Plantar,
Other
Conduit Prosthetic, Vein Prosthetic: Polyester,
PTFE, heparin bonded;
Cryopreserved allograft;
Vein: great saphenous
reversed, in situ,
translocated; femoral
vein; small saphenous;
arm vein
Add number of vein
segements used or UDI
identiﬁcation of
prosthetic graft
7)
Endarterectomy
Endarterectomy
Location for
Right/Left Leg
Aorta, common iliac, external
iliac, common femoral,
profunda femoral, superﬁcial
femoral, Popliteal
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Table 1-continued
Category Variable Reporting Level 1 Reporting Level 2 Reporting Level 3 Comments Reference
Patch Used No, Yes None, Polyester, PTFE,
heparin bonded, Bovine
pericardium, Autogenous
vein
UDI identiﬁcation of
prosthetic patch
8) Catheter
based
Intervention
Access Site(s) Femoral, Popliteal, Pedal,
Arm
Femoral Retrograde,
Femoral Antegrade,
SFA, Popliteal, Dorsal
Pedal, Posterior Tibial,
Brachial, Radial,
Axillary, Graft, Femoral
Retro to Antegrade,
Femoral Ante to
Retrograde
Largest Sheath
Size
French size number
Intervention Type Balloon angioplasty, drug
coated balloon, bare metal
stent, drug eluting stent,
covered stent, atherectomy,
other
Balloon angioplasty, drug
coated balloon, bare
metal stent, drug eluting
stent, mechanical
thrombectomy, covered
stent, brachytherapy,
atherectomy, laser
assisted angioplasty,
aspiration, scoring
balloon, cutting balloon,
cryoplasty, other
GUDID identiﬁcation
of device
Planned Adjunct
Procedure
No, Yes None, Thrombolysis
Pharmacological,
Thrombolysis Mechanical,
Suction Thrombectomy,
Embolic Protection
Device, IVUS, CTO-Device,
Bypass, Endarterectomy
GUDID identiﬁcation
of device
Closure Device No, Yes If Yes: List Device Name GUDID identiﬁcation
of device
Unplanned
Procedure for
Complication
Bailout Stent, Bailout Stent
graft
None, Thrombolysis
Pharmacological,
Thrombolysis Mechanical,
Suction Thrombectomy,
Embolic Protection
Device, IVUS, CTO-Device,
Bypass, Endarterectomy
GUDID identiﬁcation
of device
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Final Technical
Result
Successful (Stenosis  30%),
Stenosis > 30% or 10mm
Gradient, Target Lesion
Occlusion, Failure (unable to
cross or deploy device)
Bollinger Score: Complete
occlusion (1), Stenosis >
50% of lumen (2), Stenosis
of 25e50% of lumen (3),
 25% stenosis of lumen
(4), Failure (unable to
cross or deploy device)
Including only treated region Bollinger A, Breddin K, Hess H,
Heystraten FM, Kollath J,
Konttila A, et al.
Semiquantitative assessment of
lower limb atherosclerosis from
routine angiographic images.
Atherosclerosis. 1981;38
(3e4):339e46.
9)
Complications
Unplanned
Amputation for
Right/Left Leg
No, Minor Amputation,
Major Amputation
Level: Toe(s),
transmetatarsal, below
knee, through knee,
above knee, higher of R/L
leg
Amputation that resulted
from a complication or
abrupt change in disease
severity that was not
anticipated at the time of the
procedure
Site or Graft
Thrombosis for
Right/Left Leg
No, Yes If Yes: No Treatment,
Medical Treatment,
Interventional Treatment,
Surgical Treatment
Site or Graft
Stenosis for
Right/Left Leg
No, Yes If Yes: No Treatment,
Medical Treatment,
Interventional
Treatment, Surgical
Treatment
Graft Stenosis is deﬁned
as  70% diameter reducing
stenosis by Doppler
Ultrasonography, CT
Angiography, MR
Angiography or Fluoroscopy
Distal
Embolisation for
Right/Left Leg
No, Yes If Yes: No Treatment,
Medical Treatment,
Interventional Treatment,
Surgical Treatment
Target Lesion
Dissection for
Right/Left Leg
No, Yes If Yes: No Treatment,
Medical Treatment,
Interventional Treatment,
Surgical Treatment
Device Failure No, Yes If Yes: Failure to Deploy,
Fracture, Rupture, Other
Bleeding,
Hematoma,
Pseudoaneurysm
No, Yes If Yes: Minor, Transfusion,
Thrombin Injection,
Surgical Treatment
Compartment
Syndrome
No, Yes If Yes: Medical, Surgical
Treatment
Wound Infection No, Yes If Yes: Medical, Surgical
Treatment
Myocardial
Infarction
No, Yes If Yes: Troponin only
(NSTEMI), ECG (STEMI) or
Clinical Symptoms
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Table 1-continued
Category Variable Reporting Level 1 Reporting Level 2 Reporting Level 3 Comments Reference
Stroke No, Yes If Yes: Minor, Major Modiﬁed Rankin level As deﬁned byEaston et al.
(2009).
Easton JD, Saver JL, Albers GW,
Alberts MJ, Chaturvedi S,
Feldmann E, et al. Deﬁnition and
evaluation of transient ischemic
attack: a scientiﬁc statement for
healthcare professionals from
the American Heart Association/
American Stroke Association
Stroke Council; Council on
Cardiovascular Surgery and
Anesthesia; Council on
Cardiovascular Radiology and
Intervention; Council on
Cardiovascular Nursing; and the
Interdisciplinary Council on
Peripheral Vascular Disease. The
American Academy of Neurology
afﬁrms the value of this
statement as an educational tool
for neurologists. Stroke; a journal
of cerebral circulation.
2009;40(6):2276e93.
New Dialysis
Required
No, Yes No, Acute In hospital only,
Chronic Dialysis
Any acute renal replacement
therapy for acute kidney
injury (intermittent/
continuous,
haemodiaﬁltration,
haemoﬁltration,
haemodialysis etc.).
Death No, Yes If Yes: Death caused by
procedure?
10) Follow up Follow up Date Day (dd), month (mm), and
year (yyyy) of the procedure
Used to calculate duration of
follow up for subsequent
analysis and de-identiﬁed
data sharing. If regulations do
not allow date collection,
follow up duration (months)
can be substituted.
Death No, Yes If Yes: Date of Death If Yes: Procedure
related, Not Procedure
related
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Functional Status Full activity, Light Work,
Self Care, Assisted Care,
Bedbound
Add disease speciﬁc
quality of life survey,
such as Vascu-Qol-6
A person’s level of
functioning in terms of their
ability to care for themself,
daily activity, and physical
ability (walking, working
etc.).
Oken MM, Creech RH, Tormey
DC, Horton J, Davis TE,
McFadden ET, et al. Toxicity and
response criteria of the Eastern
Cooperative Oncology Group.
Am J Clin Oncol. 1982;5(6):649
e55.
Nordanstig J, Wann-Hansson C,
Karlsson J, Lundström M,
Petterson M, Morgan MBF.
Vascular Quality of Life
Questionnaire-6 faciliates
health-related quality of life
assessment in peripheral arterial
disease. J VascSurg 2014;59:
700-7.
Ambulation Fully ambulatory,
Ambulate with Prosthesis,
Ambulate with Assistive
device, Wheelchair,
Bedbound
Add walking distance
survey such as Walking
Improvement
Questionnaire or GPS
monitored walking
Symptoms for
Right/Left Leg
Modiﬁed Rutherford-
Classiﬁcation: Asymptomatic,
Mild Claudication, Moderate
Claudication (> 200m),
Severe Claudication (<
200m), Ischaemic Rest Pain,
Ulcer/Necrosis, Non-healing
Amputation, Both Ulcer/Non-
healing Amputation, Acute
Ischaemia
Level 1 Modiﬁed Rutherford !need to ref RAPID for the
modiﬁed Rutherford!
Foot Infection for
Right/Left Leg
No, Yes If Yes: Grade 0 None,
Grade 1 Mild, Grade 2
Moderate, Grade 3 Severe
Mills, Joseph L. Sr., MD, et al.
(2014). The Society for Vascular
Surgery Lower Extremity
Threatened Limb Classiﬁcation
System: Risk Stratiﬁcation Based
on Wound, Ischemia, and Foot
Infection (WIfI). Journal of
Vascular Surgery, Volume 59
(Issue 1) pp.220-pp.234.e2,
https://doi.org/10.1016/j.jvs.
2013.08.003
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Table 1-continued
Category Variable Reporting Level 1 Reporting Level 2 Reporting Level 3 Comments Reference
Tissue Loss
Severity for Right/
Left Leg
If Yes: None, Grade 1,
Shallow, Grade 2, Deep,
Grade 3, Extensive
Mills, Joseph L. Sr., MD, et al.
(2014). The Society for Vascular
Surgery Lower Extremity
Threatened Limb Classiﬁcation
System: Risk Stratiﬁcation Based
on Wound, Ischemia, and Foot
Infection (WIfI). Journal of
Vascular Surgery, Volume 59
(Issue 1) pp.220-pp.234.e2,
https://doi.org/10.1016/j.jvs.
2013.08.003
Amputation for
Right/Left Leg
No, Minor, Major If Yes: Level: Toe(s),
Transmetatarsal, Below
Knee, Through Knee,
Above Knee, Higher if
Right/Left Leg
If Yes: Date of
Amputation
Graft/Site Patency
for Right/Left Leg
No, Yes Method of Assessment
(Clinical Examination, ABI,
Ultrasound, MRA, CTA,
Fluoroscopy, Other)
Patency of the treated index
lesion.
Graft/Site Re-
Intervention for
Right/Left Leg
No, Yes If Yes: Interventional,
Surgical, Both
If Yes: Date of Re-
Intervention
Major Adverse
Cardiac Events
(MACE, MACCE)
No, Yes If Yes: Stroke, MI, CABG,
PCI
If Yes: Date of
Coronary Procedure or
Death
Composite endpoint: Any
major adverse cardiac or
cerebrovascular event
(MACE, MACCE) such as all
cause death, myocardial
infarction, stroke, or coronary
vessel revascularisation.
Conte MS, Geraghty PJ, Bradbury
AW, Hevelone ND, Lipsitz SR,
Moneta GL, et al. Suggested
objective performance goals and
clinical trial design for evaluating
catheter-based treatment of
critical limb ischemia. J Vasc
Surg. 2009;50(6):1462e73 e1-3.
Kip KE, Hollabaugh K, Marroquin
OC, Williams DO. The problem
with composite end points in
cardiovascular studies: the story
of major adverse cardiac events
and percutaneous coronary
intervention. Journal of the
American College of Cardiology.
2008;51(7):701e7.
Procedure related
Re-Admission
No, Yes If Yes: For infection,
Treatment Failure,
Systemic Complication
If Yes: Date of Re-
Hospitalisation
Any hospital readmission or
rehospitalisation after
discharge.
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International Consortium of Vascular Registries 233(see Table 1). Some data elements, such as urgency of
treatment and type of procedure were judged sufﬁciently
important to always be required (level 1).
Statistical analyses were performed with SPSS Statistics
software version 23.0 (IBM, Armonk, NY, USA).
RESULTS
Thirty-one experts were contacted and 25 accepted and
completed the ﬁrst online survey. In total, 187 items were
submitted by them and were included in the panel dis-
cussion (Table 2). The items were reviewed by the expert
panel and subsequently sorted into 11 main topics: (i) pa-
tient characteristics; (ii) comorbidities; (iii) current medica-
tions; (iv) lesion treated; (v) procedure; (vi) bypass; (vii)
endarterectomy; (viii) catheter based intervention; (ix)
complications; (x) follow up. The panel comprised vascular
surgeons representing their national registry in ICVR, from
three continents, 14 countries, and 18 institutions. The ﬁnal
number of data elements was not speciﬁed a priori. All
panel experts (100%) completed rounds 1e4 and 18 (90%)
completed round 5. The Delphi process (Fig. 1) resulted in
the ICVR suggested data set for PAD revascularisation reg-
istries with different levels of potential detail for each var-
iable (Table 1). After two Delphi rounds, 68 items were
designated twice as “agree” or “strongly agree”, whereas 60
items were designated twice as “disagree” or “strongly
disagree”. After ﬁve Delphi rounds, a total of 79 items were
included in the recommended data set, of which 65 were
included in the level 1 version, with an additional 14
included with more data speciﬁcity at the level 2 and 3
versions (Table 1). For example interventional device data
can be recorded as level 1, which reports devices by class
(plain angioplasty, drug coated balloon angioplasty, athe-
rectomy, stent, etc.); level 2, which includes adjuncts such
as embolic protection; and level 3, which records the Global
Unique Device Identiﬁcation Database.
It was recommended that all registries create an option
to indicate that the state of the variable is “unknown”, in
order to differentiate omitted from unknown data, and not
force users to choose an option when it is unclear. For
simplicity, the “unknown” options for each variable have not
been included in Table 1.
DISCUSSION
In this modiﬁed Delphi study with international experts,
consensus was achieved on items to be collected in regis-
tries on peripheral arterial revascularisation. Sixty-ﬁve items
were recommended for a minimum core (level 1) data set
with an additional 14 variables with increased speciﬁcation
recommended for the optimum dataset (level 2e3). Ac-
cording to the existing literature and methodological rec-
ommendations, the minimum and optimum number for
Delphi studies is two rounds. Regarding the panel size, at
least 6e11 members are usually recommended to work
efﬁciently. In this Delphi study more experts were included
(n ¼ 25) and there were more rounds (n ¼ 5), emphasizing
the rigor of the approach to address the complexity of the
Table 2. 187 items submitted by the expert panel or identiﬁed by
the literature review.
Date of admission
Date of procedure
Date of discharge
Mode of admission (e.g. emergency vs. elective)/
Urgency of the procedure
Performance site
Intensive care unit LOS
Special discipline responsible for hospital treatment
Hospital capacity/volume/teaching status
Discharge destination
Age (Birth Date)
Sex/Gender
Income
Occupation
Housing
Functional status
Ambulation
Nursing status
Migration background
Race and ethnicity
Education
Health insurance status
Walking distance
Existence of rest pain
Existence of ulcers
Existence of gangrene
Existence of infection
Fontaine classiﬁcation (symptoms of index leg)
Rutherford classiﬁcation (symptoms of index leg)
Tissue loss severity (for index leg)
WIfI Score
Texas classiﬁcation
Wound depth
Angiosome
Acute limb ischaemia (ALI)
Ankle brachial index (ABI)
Toe pressure
Oscillographics
Transcutaneous oxygen measurement (tcp O2)
Duplex ultrasound
Contrast enhanced CT angiography (SCTA)
Contrast enhanced MR angiography (MRA)
Invasive digital subtraction angiography (DSA)
TASC classiﬁcation
Exact location of treated lesions/artery treated or bypassed
Side for each lesion treated
Exact location of all lesions (even untreated)
Grade of stenosis
Length of stenosis
Inﬂow quantiﬁcation
Outﬂow quantiﬁcation (from treated artery)
Genuine vessel or graft/artery vs. graft
Pretreatment of lesion
Laboratory ﬁndings (e.g. cholesterol, HDL, platelet count,
haemoglobin)
Ever smoked/Tobacco use
Current smoking/Tobacco use
Diabetes type 1
Diabetes type 2
Hypertension
Hyperlipidemia
Weight (or Body Mass Index)
Height (or Body Mass Index)
ASA Grade (Risk score: American Society of Anesthesiologists)
Renal function
Dialysis
Chronic obstructive pulmonary disease (COPD)
Myocardial infarction (MI)
Congestive heart failure (CHF)
Atrial ﬁbrillation or ﬂutter (AF)
Cardiac arrhythmia
Pacemaker, deﬁbrillator, orthopedic endoprosthesis or other
artiﬁcial material
Coronary artery disease (CAD)/Ischaemic heart disease
History of stroke or TIA
History of PAD revascularisation
History of acute limb ischaemia
History of amputation
Open wound or wound infection
History of vascular procedures
Aspirin
P2Y12/Clopidogrel/Other platelet inhibitor
Other platelet inhibitors
Vitamin K antagonists
New oral anticoagulants
Low dose heparin (not procedural)
High dose heparin (not procedural)
Beta blockers
ACE inhibitors or sartans
Statin/Lipid lowering agents
PGE1 infusions
Cilostazol
Naftidrofuryl oxalate
Pentoxifylline
Inositol nicotinate
Special discipline performing the procedure
Level of residency supervision
Pre-treatment of lesion
Side of intervention
Principal anaesthesia technique
Intra-procedural heparin
Additional anaesthesia technique
Operation time
Type of main endovascular procedure
Hybrid procedure
Type of devices used
Instructions for Use (IFU) followed
Detailed device information (includes length and diameter
of different devices)
Atherectomy device
PTA device
Stent device
Distal protection device
Embolic protection device
Chronic total occlusion (CTO) device
Access site and approach
Access guidance
Largest sheath size
Use of duplex ultrasound (access)
Information about sheath used
Information about guidewire used
Planned adjunctive procedure
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Thrombolysis
Mechanical thrombectomy
Additional approach (e.g. Nitro)
Completion angiography performed
Final technical result (includes technical success)
Dose area product (DAP)/Radiation dosage
Treatment aborted or incomplete
Acute conversion to open surgery
Patency
Closure device
Type of main open procedure
Hybrid procedure
Access site and approach
Diathermia or ligature used for cut down
Existence of infection
Conduit
Type of bypass
Type of prosthetic grafts used
Type and location of vein graft
Instructions for Use (IFU) followed
Type of surgical suture material
Proximal anastomosis
Distal anastomosis
Blood loss
Re-intervention of bypass
Completion angiography performed
Treatment aborted or incomplete
Acute conversion to endovascular procedure
Patency
Dissection
(Pseudo)Aneurysm
Arteriovenous ﬁstula
Distal embolisation
Perforation
Bleeding
Myocardial infarction (MACE)
Death (MACE)
Stroke or TIA (MACE)
Major amputation (MALE)
Minor amputation (MALE)
Re-operation or re-intervention
Transfusion
Acute limb ischaemia/Lower extremity ischaemia
Device fracture or rupture
Compartment syndrome
Nerve injury
Wound infection or graft infection
Lymphoedema
Lymph ﬁstula or seroma
Re-intervention open surgery
Re-intervention endovascular
Pneumonia
Deep venous thrombosis (DVT)
Pulmonary embolism
Acute renal replacement therapy
Delirium
Stent or graft thrombosis
Gastrointestinal complications
MACE
MALE
Patency
Limb salvage
Quality of life
Walking distance
Rehospitalisation
Re-intervention
Infection
Ankle brachial index (ABI)
Destination at discharge/discharge destination
International Consortium of Vascular Registries 235research questions. For example, the additional three
rounds resulted in 58 positive or negative recommenda-
tions that inﬂuenced the ﬁnal result. An existing and well
established international research collaboration of ICVR was
used in order to include a high proportion of vascular reg-
istry experts. In addition to two face to face meetings, all
comments of the panel experts were shared electronically.
This innovative approach made the processes rigorous and
efﬁcient, considering the fact that international experts
from different time zones participated in this Delphi study.
Importantly, the Delphi process resulted in a reduction
from 187 items originally included in PAD registries across
the ICVR to 79 items in the optimum data set. This is still a
large number of variables after the consensus process and
may pose a hurdle owing to the burden of data collection.
However, considering the complexity of the PAD, and the
abundance of medical and surgical treatment alternatives, a
more comprehensive data collection is necessary to allow
meaningful data analysis. Ultimately, the trade-off between
complexity and practicality was challenging and proved to
be even more difﬁcult when designing a registry database
for PAD than for AAA or carotid artery disease.
The key to collaboration and data sharing among regis-
tries is harmonisation of data elements, deﬁnitions, and
method for similarly recording each variable. While each
registry would prefer to register the most detailed data
possible, real world practice and current lack of ability to
easily extract uniform data from all electronic medical re-
cord (EMR) systems makes this impractical. For this reason,
it is valuable to recommend not only a minimum core data
set (and uniform deﬁnitions) that can be used by all regis-
tries, but also to recommend more detailed categories
(levels) for data recording as registries mature and EMR
extraction becomes more feasible. It is important that these
higher levels of data collection harmonise with core levels
so that all data can be merged at some level. The authors
believe that the current proposal of core to optimum data
collection “levels” is a novel contribution that could be
valuable for other specialties.
It is recognised that the number and selection of data
elements is contingent on the intended uses of the registry.
A PAD revascularisation registry designed for quality
improvement would probably have different elements or
fewer granular data than one established for clinical
research or device evaluation. In this work there was an
attempt to balance the competing interests of inclusiveness
with the practicality of data entry. The concept of different
levels of modern web based registries with contingent
variables already enables efﬁcient data entry, but there is
much work to be done. In the future, it is expected that
Figure 1. Flow chart of the modiﬁed Delphi study.
236 Christian-Alexander Behrendt et al.registries will integrate with EMR systems and claims data
to allow more automated data capture to minimise the
work of data entry. Clearly, such future developments facing
big-data applications will need to meticulously deal with
data privacy and safety concerns.16
Harmonisation of registries will allow for more meaningful
comparisons of practice patterns, medical device perfor-
mance, and outcomes across countries. Such collaboration
will improve our ability to generate real world evidence and
design registry based studies of peripheral vascular in-
terventions. In the future, registry based studies may sup-
plement the evidence gained from RCTs and prospective
cohort studies. Similar work has been reported by the Reg-
istry Assessment of Peripheral Arterial Devices (RAPID)
group for multispecialty collaboration within USA.17,18 The
ICVR-recommended data set has many agreements with
data elements and deﬁnitions in RAPID, which is focused on
device evaluation for peripheral vascular intervention in
USA. The current ICVR database recommendations extend
those of RAPID to encompass both open and endovascular
revascularisation and for international studies, while still
allowing device evaluation. These efforts provide an impor-
tant opportunity for global harmonisation of clinical data to
improve vascular health care. Existing ICVR registry mem-
bers are committed to adopting these data elements as the
next stage of evolution for ICVR.CONCLUSIONS
This large scale modiﬁed Delphi study among international
vascular registry specialists achieved a consensus agree-
ment on a minimum core and optimum data set for regis-
tries evaluating peripheral arterial revascularisation. It
reduced the overall number of initially suggested variables
by nearly half. Global harmonisation of registry infrastruc-
ture and deﬁnition of items will overcome limitations
related to single country investigations and has the poten-
tial to speed up and enhance acquisition of real world ev-
idence. National registries in the ICVR plan to incorporate
these core data elements into their PAD registries to in-
crease the opportunity for future collaboration.
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